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VACCINES AND ANTIVIRAL AGENTS
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Virus 1 Vaccine Strain VC2 Expressing
Equine Herpesvirus 1 (EHV-1)
Glycoprotein D Generates Anti-EHV-1
Immune Responses in Mice
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Ingeborg Langohr,a Fabio Del Piero,a Jacqueline Ferracone,b Alma A. Roy,a
Konstantin G. Kousoulasa
Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton
Rouge, Louisiana, USAa; Department of Clinical Studies and Pathology, University of Pennsylvania School of
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Vaccination remains the best option to combat equine herpesvirus 1
(EHV-1) infection, and several different strategies of vaccination have been investigated and developed over the past few decades. Herein, we report that the liveattenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown
to be unable to enter into neurons and establish latency in mice, can be utilized as
a vector for the heterologous expression of EHV-1 glycoprotein D (gD) and that the
intramuscular immunization of mice results in strong antiviral humoral and cellular
immune responses. The VC2–EHV-1– gD recombinant virus was constructed by inserting an EHV-1 gD expression cassette under the control of the cytomegalovirus
immediate early promoter into the VC2 vector in place of the HSV-1 thymidine kinase (UL23) gene. The vaccines were introduced into mice through intramuscular injection. Vaccination with both the VC2–EHV-1– gD vaccine and the commercially
available vaccine Vetera EHVXP 1/4 (Vetera; Boehringer Ingelheim Vetmedica) resulted in the production of neutralizing antibodies, the levels of which were signiﬁcantly higher in comparison to those in VC2- and mock-vaccinated animals (P ⬍
0.01 or P ⬍ 0.001). Analysis of EHV-1-reactive IgG subtypes demonstrated that vaccination with the VC2–EHV-1– gD vaccine stimulated robust IgG1 and IgG2a antibodies
after three vaccinations (P ⬍ 0.001). Interestingly, Vetera-vaccinated mice produced
signiﬁcantly higher levels of IgM than mice in the other groups before and after
challenge (P ⬍ 0.01 or P ⬍ 0.05). Vaccination with VC2–EHV-1– gD stimulated strong
cellular immune responses, characterized by the upregulation of both interferonand tumor necrosis factor-positive CD4⫹ T cells and CD8⫹ T cells. Overall, the data
suggest that the HSV-1 VC2 vaccine strain may be used as a viral vector for the vaccination of horses as well as, potentially, for the vaccination of other economically
important animals.
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IMPORTANCE A novel virus-vectored VC2–EHV-1– gD vaccine was constructed using

the live-attenuated HSV-1 VC2 vaccine strain. This vaccine stimulated strong humoral
and cellular immune responses in mice, suggesting that it could protect horses
against EHV-1 infection.
KEYWORDS EHV-1, HSV-1, equine herpesvirus, live vector vaccines, glycoprotein D,
immune response, mouse model
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quine herpesvirus 1 (EHV-1) belongs to the Alphaherpesvirinae subfamily and is an
important ubiquitous enzootic equine pathogen causing epidemic abortion, perinatal mortality, respiratory disease, and, occasionally, neurological disease in horses,
resulting in signiﬁcant economic losses to the horse industry. EHV-1 infection elicits a
local immune response at the primary site of replication, as well as systemic humoral
and cellular immune responses. EHV-1 infection of naive animals induces protective
immunity against reinfection lasting 4 to 8 months after the initial acute infection (1).
EHV-1 glycoproteins facilitate multiple aspects of the viral life cycle, including mediation of the fusion of the viral envelope with cellular membranes, intracellular virion
morphogenesis, egress, cell-to-cell spread, and virus-induced cell fusion. Thus, these
proteins are major antigenic determinants for both humoral and cellular immune
responses and have been utilized as subunit vaccines (2–4). Speciﬁcally, immunization
with EHV-1 glycoprotein D (gD) has been shown to generate protective immune
responses in mice and horses (3, 5–11). EHV-1 and herpes simplex virus 1 (HSV-1)
glycoproteins D are required for entry into cells and cell-to-cell fusion, a function which
is conserved in most but not all alphaherpesviruses (12).
Despite regular and widespread vaccination, outbreaks of EHV-1 continue to occur.
Current commercial vaccines that contain inactivated virus confer only partial clinical
and virological protection against EHV-1 respiratory infections because they do not
stimulate cellular immune responses, speciﬁcally, cytotoxic T cells that can control
cell-associated viremia and virus dissemination from the respiratory tract (13). Virusvectored vaccines express antigens within the infected cell that can be presented via
major histocompatibility complex (MHC) class I (MHC-I; endogenous) and class II (MHC-II;
exogenous) antigen-processing routes, stimulating both humoral and cell-mediated immune responses (14). Herein, we report the construction and testing of an effective
HSV-1-vectored vaccine designed to prevent EHV-1 infections. The HSV-1 VC2 strain
contains gK with the deletion of amino acids 31 to 68 and the deletion of the
amino-terminal 19 amino acids of UL20, which render the virus unable to enter into the
distal axons of ganglionic neurons, while the virus replicates efﬁciently in epithelial and
ﬁbroblast cells and generates robust and protective immune responses in mice (15) and
guinea pigs (B. A. Stanﬁeld and K. G. Kousoulas, unpublished data).
The mouse model of EHV-1 infection has been used to investigate the vaccine
potentials of various EHV-1 immunogens, the effects of antiviral agents on EHV-1
infection, and the pathogenicities of EHV-1 strain variants and deletion or insertional
mutants (16–18). The lung histopathology in EHV-1-infected mice is similar to that in
infected horses and is characterized by an acute necrotizing alveolitis and bronchiolitis
and eosinophilic intranuclear inclusion bodies in bronchiolar epithelial cells (19, 20).
Although the mouse model of EHV-1 infection is not ideal, its extensive use has
contributed toward the development of vaccine strategies. Herein, we show that the
live-attenuated HSV-1 VC2 vaccine strain expressing EHV-1 gD can efﬁciently infect
equine cells and generates strong and protective anti-EHV-1 immune responses in mice
that may also protect horses against EHV-1 infection.
RESULTS
Construction and characterization of the VC2–EHV-1– gD vaccine. The EHV-1 gD
gene under the control of the human cytomegalovirus (CMV) immediate early promoter was inserted in place of the thymidine kinase (UL23) gene (Fig. 1a). The gene
insertion was veriﬁed by PCR-assisted sequencing of the insertion site, as well as by
complete genomic sequencing of parental and mutant viral genomes (not shown) to
ensure the absence of any spurious mutations. The virus was able to express the EHV-1
gD efﬁciently in both Vero and NBL-6 cells, as determined by the detection of both
anti-gD-speciﬁc antibody and anti-FLAG antibody in Western immunoblots of infected
cell extracts (Fig. 1b). VC2–EHV-1– gD replicated efﬁciently in both Vero and equine
NBL-6 cells, approaching similar titers at 48 h postinfection (hpi) at both low and high
multiplicities of infection (MOIs; 0.1 and 5, respectively) (Fig. 2). However, VC2–EHVJune 2017 Volume 91 Issue 12 e02445-16
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1– gD replicated signiﬁcantly more slowly than the parental VC2 virus, reﬂected in their
relative plaque sizes produced at 48 hpi (Fig. 3).
Monitoring of clinical disease symptoms. It has previously been reported that the
parental VC2 vaccine strain did not produce any signiﬁcant clinical disease after
intramuscular administration in mice (15). Similarly, there were no adverse clinical signs
noted after intramuscular injection of either VC2 or VC2–EHV-1– gD in mice throughout
the vaccination period (8 weeks). In addition, during the vaccination period there were
no signiﬁcant weight differences among the groups (data not shown). The mice in all
groups started to exhibit weight loss after challenge with wild-type EHV-1, although no
clinical signs, such as fur rufﬂing and heavy breathing, were observed during the
6-week interval postchallenge. The unvaccinated group regained weight more slowly
than the other three groups (Fig. 4).

FIG 2 Replication kinetics of VC2 versus VC2–EHV-1– gD. Replication kinetics were produced for VC2 and VC2–EHV-1– gD
at both a high MOI (MOI, 5) and a low MOI (MOI, 0.1) on Vero and NBL-6 cells.
June 2017 Volume 91 Issue 12 e02445-16
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FIG 1 (a) Schematic of the VC2–EHV-1– gD genome. The schematic shows the insertion of the EHV-1 gD
gene in place of the UL23 (thymidine kinase) gene. The 3⫻ FLAG gene segment was inserted in frame
to be expressed at the carboxyl terminus of gD. The locations of other relevant genes are shown. UL24,
nuclear protein; TR, terminal repeat; UL, unique long region; IRL, left inverted repeat; IRR, right inverted
repeat; US, unique short region. (b) Western immunoblots of gD expression. EHV-1 gD expression was
detected by anti-FLAG antibodies or anti-EHV-1 gD 19-mer polyclonal antibodies (kindly provided by
Dennis O’Callaghan, Louisiana State University Health Sciences Center, Shreveport, LA). Lanes 1 and 2,
cellular extracts from VC2–EHV-1– gD- or VC2-infected NBL-6 cells detected by anti-FLAG antibody; lanes
3 and 4, cellular extracts from VC2–EHV-1– gD- or VC2-infected Vero cells detected by anti-FLAG
antibody; lanes 5 and 6, cellular extracts from VC2–EHV-1– gD- or VC2-infected NBL-6 cells detected by
a rabbit antibody generated against a 19-amino-acid peptide of EHV-1 gD; lanes 7 and 8, cellular extracts
from VC2–EHV-1– gD- and VC2-infected Vero cells detected by anti-EHV-1 gD (19-mer); lane M, molecular
mass markers (the numbers on the left are molecular masses [in kilodaltons]).

Journal of Virology

FIG 3 Plaque morphology of VC2 versus VC2-EHV-gD on Vero and NBL-6 cells at 72 h postinfection. Both viruses grew on Vero and NBL-6
cells, and VC2-EHV-gD produced smaller plaques than VC2.

Characterization of humoral immune responses. Antisera from all groups of mice
were individually tested at a 1:20 dilution. A boost vaccination increased serum
neutralization signiﬁcantly. The animal groups vaccinated with the commercially available vaccine Vetera EHVXP 1/4 (Vetera; Boehringer Ingelheim Vetmedica), VC2, and
VC2–EHV-1– gD exhibited signiﬁcantly higher virus-neutralizing (VN) activities than the

FIG 4 The effects of vaccination on the weights of mice in the Vetera-, VC2-, and VC2–EHV-1– gDvaccinated groups and the unvaccinated groups were monitored daily after challenge with the EHV-1
clinical isolate. Statistical analyses of the differences between VC2–EHV-1– gD-vaccinated and unvaccinated mice were performed on day 7 (P ⬍ 0.05), day 9 (P ⬍ 0.01), day 11 (P ⬍ 0.05), day 23 (P ⬍ 0.01),
day 27 (P ⬍ 0.05), and day 31 (P ⬍ 0.05). P values were determined by one-way analysis of variance
followed by the Newman-Keuls multiple-comparison test.
June 2017 Volume 91 Issue 12 e02445-16
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unvaccinated group after the ﬁrst immunization. VC2–EHV-1– gD vaccination increased
the VN activity (33.6%) in mice after three consecutive vaccinations, and the VN activity
was similar to that achieved with the commercial whole-virus vaccine (32.6%). Overall,
the Vetera- and VC2–EHV-1– gD-vaccinated groups exhibited similar virus-neutralizing
activities during the entire vaccination period, and these were signiﬁcantly higher than
those produced by the unvaccinated group (P ⬍ 0.01 or P ⬍ 0.001) and the VC2vaccinated group at week 8 (P ⬍ 0.01) (Fig. 5).
Serum obtained from the VC2–EHV-1– gD-immunized group generated strong
antigen-speciﬁc signals (Fig. 6a), which were signiﬁcantly higher than those produced
by the Vetera-vaccinated group (P ⬍ 0.01), the unvaccinated group (P ⬍ 0.001), and the
VC2-vaccinated group (P ⬍ 0.001). Sera from all animals were also tested for their ability
to detect EHV-1 antigens in infected Vero and NBL-6 cells. Sera from VC2-vaccinated
animals demonstrated a higher reactivity in Vero and NBL-6 cells than sera from all
other groups, in which reactivity was determined by indirect immunoﬂuorescence to

FIG 6 Anti-EHV-1 activities. Sera obtained from mice in the Vetera-, VC2-, and VC2–EHV-1– gD-vaccinated groups and the unvaccinated
group before and after challenge were diluted 1:20 in growth medium and tested for their ability to react with EHV-1-infected RB13 cells.
FACS data were analyzed by one-way analysis of variance followed by the Newman-Keuls multiple-comparison test. **, P ⬍ 0.01; ***, P ⬍
0.001.
June 2017 Volume 91 Issue 12 e02445-16
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FIG 5 Virus-neutralizing activities. All serum samples were diluted 1:20 in growth medium and tested for
the ability to neutralize approximately 100 PFU of EHV-1. Data were statistically analyzed by one-way
analysis of variance followed by the Newman-Keuls multiple-comparison test. *, P ⬍ 0.05; **, P ⬍ 0.01;
***, P ⬍ 0.001.
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assess the ability of serum from vaccinated and unvaccinated animals to detect EHV-1
antigens (Fig. 7). Overall, sera from the VC2–EHV-1– gD-immunized group produced the
strongest EHV-1-speciﬁc IgG antibody signals when the signals from all groups were
compared (Fig. 6b), in agreement with indirect ﬂuorescent-antibody-facilitated detection of EHV-1 antigens in infected Vero and NBL-6 cells (Fig. 8).
The IgG1 levels produced in mice vaccinated with VC2–EHV-1– gD were signiﬁcantly
higher than those produced in the other groups of mice after three vaccinations and
after challenge (Fig. 9a and b) (P ⬍ 0.001). The IgG2a levels in the VC2–EHV-1– gDvaccinated group were also signiﬁcantly higher than those in the other groups after
three vaccinations (Fig. 9c and d) (P ⬍ 0.001), but there was no signiﬁcant difference
after EHV-1 challenge. Signiﬁcantly more IgG2b was produced by the VC2–EHV-1– gD

FIG 8 Anti-EHV-1 IFA assay. Sera obtained from mice in the Vetera-, VC2-, and VC2–EHV-1– gD-vaccinated
groups and the unvaccinated group after challenge were diluted 1:20 and tested by the IFA assay.
June 2017 Volume 91 Issue 12 e02445-16
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FIG 7 Anti-EHV-1 IFA assay. Sera obtained from mice in the Vetera-, VC2-, and VC2–EHV-1– gD-vaccinated
groups and the unvaccinated group before challenge were diluted 1:20 and tested by the IFA assay.
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TABLE 1 Peptides predicted to be BALB/c mouse MHC-I and MHC-II binding epitopes
MHC class
I
I
II

Allele
H-2-Dd
H-2-Ld
H2-IEd

Length (no. of
amino acids)
12
10
15

Position
338–349
47–56
365–379

Peptide sequence
KPPKTSKSNSTF
FPPPRYNYTI
GVILYVCLRRKKELK

group than by the other groups (P ⬍ 0.05) after three vaccinations (Fig. 9e and f) (P ⬍
0.01 or P ⬍ 0.05). Interestingly, Vetera-vaccinated animals produced signiﬁcantly higher
IgM levels than the other groups before and after challenge (Fig. 9g and h) (P ⬍ 0.01
or P ⬍ 0.05). No IgG3 or IgA was detected at a 1:100 dilution of serum from all
treatment groups.
Cellular immune responses. A surface and intercellular labeling assay was utilized
to detect the gamma interferon (IFN-␥) and tumor necrosis factor (TNF) synthesized by
CD4⫹ and CD8⫹ T cells in the presence of speciﬁc peptides (Table 1) predicted to be
MHC-I or MHC-II binding epitopes. All three peptides stimulated more IFN-␥-producing
CD4⫹ cells in the VC2- and VC2–EHV-1– gD-vaccinated groups than the Veteravaccinated and control groups after EHV-1 challenge. In the VC2–EHV-1– gD-vaccinated
group, more IFN-␥-producing CD8⫹ T cells were stimulated by peptide 1 or 3 after three
vaccinations. Also, peptide 3 stimulated more IFN-␥-producing CD8⫹ T cells in the
Vetera-vaccinated group (Fig. 10). Moreover, all three peptides stimulated more IFN␥-producing CD8⫹ cells in the VC2–EHV-1– gD-vaccinated group after EHV-1 challenge.
The peptides stimulated a cellular immune response after three vaccinations and
postchallenge. There were more TNF-producing CD8⫹ T cells in the VC2–EHV-1– gDvaccinated group than in the other groups after stimulation of peripheral blood
mononuclear cells (PBMCs) by all peptides (peptides 1, 2, and 3) at 1 week postchallenge (Fig. 11).
Immunohistochemistry of mouse lung tissues. Immunohistochemical analysis of
the lung sections revealed a signiﬁcant absence of EHV-1 antigen in the bronchiolar
epithelial cells of the Vetera- and VC2–EHV-1– gD-vaccinated groups at 4 days after
EHV-1 challenge (Fig. 12A and B). However, the lung tissues of the unvaccinated and
VC2-vaccinated groups showed a prolonged presence of the EHV-1 antigen during the
time period postchallenge. Interestingly, histopathological analysis revealed that, unlike
the Vetera-vaccinated group, the pulmonary bronchioles and vasculature in the VC2–
EHV-1– gD-vaccinated group were surrounded by reduced levels of inﬂammation at 4
days postchallenge in comparison to those in the VC2-vaccinated and unvaccinated
groups (Fig. 12A and B).
DISCUSSION
In the study described here, we explored for the ﬁrst time the use of the human
herpes simplex virus 1 (HSV-1) VC2 vaccine strain as a potential live virus vaccine to
combat EHV-1 infections. The VC2 virus was engineered to express the EHV-1 gD
glycoprotein and was shown to elicit protective humoral and cellular immune responses in mice. The work suggests that the human HSV-1 VC2 vaccine strain may be
utilized as a vector for the production of heterologous vaccines expressing immunogens that can protect horses and other animals against economically important pathogens.
The VC2-vaccinated group generated anti-EHV-1 neutralizing activity against EHV-1
infection, suggesting the presence of common immunogenic determinants between

FIG 9 In vitro analysis of the humoral immune response of the experimental groups. A colorimetric enzyme-linked
immunosorbent assay was used to analyze a 1:100 dilution of serum from the Vetera-, VC2-, and VC2–EHV-1– gDvaccinated mice and unvaccinated mice for EHV-1-reactive polyclonal IgG1, IgG2a, IgG2b, and IgM produced 8 weeks
after the ﬁrst vaccination (before challenge) and 1 week after challenge. Statistical comparisons were conducted using
one-way analysis of variance followed by the Newman-Keuls multiple-comparison test. *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍
0.001. OD, optical density.
June 2017 Volume 91 Issue 12 e02445-16
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FIG 10 In vitro analysis of the cellular immune responses of the experimental groups. CD4⫹ and CD8⫹ T cells among splenocytes from
the Vetera-, VC2-, and VC2–EHV-1– gD-vaccinated groups and the unvaccinated group were obtained after three vaccinations, stimulated
with EHV-1 gD peptides, and analyzed by ﬂow cytometry.

HSV-1 and EHV-1. HSV-1 and EHV-1 share a number of conserved genes and an overall
genomic arrangement characteristic of the alphaherpesvirus subfamily. However, individual homologous viral proteins differ substantially in their primary sequences. Speciﬁcally, the HSV-1 and EHV-1 gDs exhibit 19.2% identity and 31.5% similarity. However,
alignment of HSV-1 gD sequences indicates the conservation of certain continuous
amino acid segments that could provide shared immunogenic responses. In addition,
on the basis of the overall structure conservation of EHV-1 and HSV-1 gDs (21, 22),
certain conformational epitopes may be conserved and may contribute to the observed
cross-neutralizing activity of VC2. Also, it is likely that a number of other viral proteins
may contribute immunogenic determinants that are common to strains and that
produce cross-neutralizing activity. VC2–EHV-1– gD stimulated strong virus-neutralizing
(VN) activity in comparison to that seen in both unvaccinated and VC2-vaccinated
animals, and this VN activity was similar to that generated by the commercial EHV-1
killed virus vaccine. It has been reported that intranasal or intramuscular immunization
with EHV-1 gD produces antigen-speciﬁc IgG responses (3, 4, 8, 10, 11, 22–25). In
addition, the presence of VN antibody prior to EHV-1 infection was shown to be
associated with a reduction in the amount and duration of nasopharyngeal virus
shedding (26, 27). Flow cytometry tests revealed that VC2–EHV-1– gD stimulated signiﬁcantly higher levels of speciﬁc anti-EHV-1 antibody than the commercial vaccine,
suggesting that this response plays a major role in conferring protection against EHV-1
infection (Fig. 6) (P ⬍ 0.001). IgM antibodies are highly cross-reactive. They are typically
produced early after an infection and are later replaced by higher-afﬁnity IgG antibodies through isotype switching (28). Mice in the Vetera-vaccinated group produced
anti-EHV-1 IgM at signiﬁcantly higher levels than the other groups before and after
challenge (Fig. 9) (P ⬍ 0.05 or P ⬍ 0.01), which may have contributed to the observed
June 2017 Volume 91 Issue 12 e02445-16
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FIG 11 In vitro analysis of the cellular immune response of the experimental groups. CD4⫹ and CD8⫹ T cells among splenocytes from
EHV-1-challenged mice from the Vetera-, VC2-, and VC2–EHV-1– gD-vaccinated groups and the unvaccinated group were stimulated
with EHV-1 gD peptides (Table 1) and analyzed by ﬂow cytometry.

virus-neutralizing activities (Fig. 5). However, the Vetera vaccine produced signiﬁcantly
lower anti-EHV-1 IgG levels than the VC2–EHV-1– gD vaccine (Fig. 6) (P ⬍ 0.01).
The IgG2a and IgG1 isotypes are markers for Th1 and Th2 responses, respectively
(29–32). The IgG subclass induced after immunization or challenge is an indirect
measure of the contribution of Th2-type cytokines relative to that of Th1-type cytokines. The production of IgG1-type antibodies is primarily induced by Th2-type cytokines, whereas the production of IgG2a-type antibodies reﬂects the involvement of
Th1-type cytokines (33). These IgG subtypes were investigated in mice before and after
EHV-1 challenge. The VC2–EHV-1– gD-vaccinated mice generated high IgG1 and IgG2a
responses before challenge. However, IgG2a levels were enhanced after challenge,
indicating a natural IgG2a response to EHV-1 infection. In comparison, mice in the other
groups developed lower levels of IgG1 and IgG2a (Fig. 9). These results indicate that the
VC2–EHV-1– gD vaccination generated a strong Th1 response priming the animals prior
to challenge. Cytotoxic T lymphocytes (CTLs) are thought to be primarily responsible for
eliminating EHV-1-infected cells (34–37). The VC2–EHV-1– gD vaccine increased the numbers of IFN-␥-producing CD8⫹ cells after stimulation by peptide 3, indicating elicitation of
anti-EHV-1 gD CD8⫹ T cell responses (Fig. 10). IFN-␥ is commonly produced by effector
CD8⫹ T lymphocytes, and upon recognition of the speciﬁc antigen, CTL activity can be
measured (38, 39). Several studies conducted in mice have demonstrated an important role
for IFN-␥ in immune protection from herpesvirus infections (40, 41). Also, IFN-␥ is critical
for innate and adaptive immunity against viral infections in general and is an important
activator of macrophages and an inducer of MHC molecule expression, while virusspeciﬁc CD8⫹ T cells are thought to produce long-lived protection (42). After in vitro
stimulation with EHV-1 gD peptides, equine PBMCs induced IFN-␥ production by a
signiﬁcantly higher percentage of samples after EHV-1 infection than preinfection. This
response was associated with an increase in virus-speciﬁc CTL activity, a critical immune
June 2017 Volume 91 Issue 12 e02445-16
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FIG 12 Histopathology of lung tissues. (A) Lung tissue showed intense inﬂammatory reactions (arrows) in the peribronchiolar and
perivascular areas in the lung parenchyma at day 4 postchallenge. (Left) H&E-stained samples from mice vaccinated with Vetera (a), VC2
(c), or VC2–EHV-1– gD (e) and unvaccinated mice (g); (right) immunohistochemistry (IHC) staining of samples from mice vaccinated with
Vetera (b), VC2 (d), or VC2–EHV-1– gD (f) and unvaccinated mice (h). Immunohistochemistry analysis shows that EHV-1 antigens were
present in the infected bronchiolar cells lining the bronchioles (h, arrows). However, lung tissue from gD-vaccinated mice appeared
histologically normal, with no appreciable amounts of viral antigens being detected (f, arrows). Photomicrographs were captured under
a ⫻200 magniﬁcation. (B) Histopathology quantiﬁcation. The degree of pulmonary inﬂammation in images of H&E-stained sections was
quantiﬁed as the pathology score (percentage), as described in Materials and Methods (n ⫽ 3 mice/group). Immunohistochemistry
staining was quantiﬁed as the percentage of EHV-1-positive bronchiolar epithelial cells in the lungs, as described in Materials and Methods
(n ⫽ 3 mice/group).

effector for the control of EHV-1 infection and disease (43). Therefore, the observed
CD8⫹ T cell response generated by the VC2–EHV-1– gD vaccine must be a strong
contributing factor limiting EHV-1 infection in mice. It remains to be tested whether
similar immune responses can be generated in horses.
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TABLE 2 Oligonucleotide primers used in this study

aBoldface

Template
EHV-1 gD
EHV-1 gD
pEPkan-S
pEPkan-S
CMV-14
CMV-14
EHV-1 gD
EHV-1 gD
EHV-1 gD
EHV-1 gD
EHV-1 gD
EHV-1 gD

Sequencea
AAGCTTGCGGCCGCGATGTCTACCTTCAAGCTTATG
AAGCTTGGATCCCGGAAGCTGGGTATATTTAAC
CTTGGTGAATTCAACTTCCCACAAGGAGAGCATATGACATGGTTGAAGTTCTGAGGATGACGACGATAAGTAGGG
CTTGGTGAATTCCAACCAATTAACCAATTCTGATTAG
GTGGCGTGAAACTCCCGCACCTCTTCGGCAAGCGCCTTGTAGAAGCGCGTCCATGTTGACATTGATTATTGAC
TTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCTCCTTCCGTGTTAAGGACAGGGAAGGGAGCAGTGG
GGCGTGTACGGTGGGAGGTCTATA
ATGCCAACGTGTGCAACGCCTATA
TTATGAAGCCCAGGCATTCGCAAG
AATTATGCCAACGTGTGCAACGC
CTGGTTCGTCTACGATGGTGGAA
AAGTCTGCACAGAACGGCTTGAC

indicates restriction enzyme sites, and underlining indicates the sequences annealing to template.

Tumor necrosis factor (TNF) or tumor necrosis factor alpha (TNF-␣) is an important
cytokine that triggers local containment of infections. The VC2–EHV-1– gD vaccine
group generated more TNF-producing CD8⫹ T cells postchallenge than the other
groups, which was in agreement with the ﬁndings described in a previous report that
showed the concurrent upregulation of TNF transcripts postinfection in EHV-1 strain
RacL11-infected mice (44). TNF stimulates endothelial cells to express proteins that
trigger blood clotting in the local small vessels, occluding them and cutting off blood
ﬂow. This physiological effect may prevent the viruses from entering the bloodstream
and spreading through the blood to organs all over the body, resulting in a reduction
in the level of EHV-1 viremia. Further studies are needed to determine the speciﬁc role
that TNF may play in the pathogenesis of EHV-1 infection.
Recently, the U.S. Food and Drug Administration (FDA) approved the Biologics
License Application for talimogene laherparepvec (Imlygic), a genetically modiﬁed
HSV-1 oncolytic viral therapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery.
The HSV-1 VC2 strain has been shown to elicit robust humoral and cellular immune
responses in mice, nonhuman primates, and guinea pigs and to confer protection
against HSV-2 challenge in mice (15), nonhuman primates (45), and guinea pigs (B. A.
Stanﬁeld et al., unpublished data). Here, we describe the use of the VC2 virus for the
production of a modiﬁed live-attenuated vaccine against EHV-1. It remains to be tested
whether VC2 is safe for use by horses and other animals. The ﬁndings of those studies
will pave the way for its use for the production of viral vector vaccines against major
pathogens of economically important animal species.
MATERIALS AND METHODS
This work was approved by the Louisiana State University (LSU) Inter-Institutional Biological and
Recombinant DNA Safety Committee (IBRDSC reference number 00615) and the Institutional Animal Care
and Use Committee (IACUC reference number 15-019).
Virus and cells. A clinical EHV-1 strain was isolated from the placenta of a Thoroughbred horse in
2008 and provided by Alma Roy of the Louisiana Animal Disease Diagnostic Laboratory (LADDL). Vero
(African green monkey kidney) and RK13 (rabbit kidney) cells were provided by LADDL and cultured
using Dulbecco modiﬁed Eagle medium (DMEM) with 5% fetal bovine serum (FBS) and 1% antibiotic
formulation (Primocin). NBL-6 (equine dermal) cells were purchased from ATCC and cultured/maintained
as instructed by ATCC.
Construction of recombinant virus. The construction and characterization of HSV-1 VC2 have been
described previously (15). The VC2 genome cloned into a bacterial artiﬁcial chromosome (BAC) plasmid
was utilized for the construction of VC2–EHV-1– gD. The VC2 virus contains gK with the deletion of amino
acids 31 to 68 as well as the deletion of the UL20 amino-terminal 19 amino acids (15). VC2 is unable to
enter into neuronal endings, while it produces protective humoral and cellular immunity that fully
protects vaccinated mice against HSV lethal disease (15). VC2–EHV-1– gD was constructed in Escherichia
coli SW105 cells, using the two-step bacteriophage lambda Red-mediated recombination system, as
described previously (15, 46). The EHV-1 gD sequence of 1,206 bp was ampliﬁed by PCR using primers
P1 and P2 (Table 2). The PCR products were digested with the restriction enzymes NotI and BamHI and
inserted into the vector CMV-14 with a 3⫻ FLAG epitope inserted in frame at the carboxyl terminus of
gD, resulting in recombinant plasmid CMV-gD. To construct CMV-gD-Kanr, the kanamycin resistance
(Kanr) gene adjoining the I-SceI site was ampliﬁed by PCR from plasmid pEPkan-S using primers P3 and
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P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
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TABLE 3 Vaccination design
Groupa
1
2
3
4

Vaccine
Naive
Vetera EHVXP 1/4b
VC2
VC2–EHV-1–gD

Dose
No vaccination
0.1 ml for primary, secondary, and third boosts
105 PFU for primary, secondary, and third boosts
105 PFU for primary, secondary, and third boosts

aFifteen

mice were included in each group.
EHVXP 1/4 (Boehringer Ingelheim Vetmedica) is an inactivated virus vaccine. It was diluted 1:1,000 in
DMEM, and 0.1 ml was used as a single dose in mice.

P4 (Table 2), digested with the restriction enzyme EcoRI, and inserted into CMV-gD (digested with EcoRI).
The CMV-gD-Kanr gene was ampliﬁed by PCR using primers P5 and P6 (Table 2) and then cloned into VC2
to replace UL23 (thymidine kinase). The kanamycin resistance cassette was cleaved after expression of
I-SceI from plasmid pBAD-I-SceI. The inserted EHV-1 gD was veriﬁed by capillary DNA sequencing by
using primers P7 to P12 (Table 2).
Synthetic peptides. BALB/c mouse MHC-I and MHC-II binding peptides were predicted by the use
of IEDB T cell epitope prediction tools (http://tools.immuneepitope.org/main/tcell/). The peptides were
synthesized at the LSU Protein Core Lab (Table 1). These peptides (ﬁnal concentration, 1 ng in each
reaction tube) were used to stimulate splenocytes from different vaccinated or challenged mice in vitro.
Vaccination. Seven-week-old female BALB/c mice were used in this study (60 mice total; 4 groups
of 15 mice each). Each mouse was identiﬁed with an ear tag. Naive animals did not get any vaccine, and
the commercial vaccine Vetera EHVXP 1/4 (Vetera; Boehringer Ingelheim Vetmedica), an inactivated virus
vaccine, was used to immunize a control group of animals. Vaccines were administered intramuscularly
(cranial thigh muscles) at 2-week intervals three times for all groups except the naive group (Table 3).
Mice were observed and weighed daily over the course of the vaccination period. Blood/serum samples
were collected from the facial vein every other week.
EHV-1 respiratory challenge in mice. Four groups of 11 mice each were challenged intranasally
with 20 l containing 5 ⫻ 107 PFU wild-type EHV-1 (10 l per nostril) at 5 weeks following the ﬁnal
administration of the vaccine. Mice were weighed daily over the course of this study and were monitored
daily for the development of clinical signs, such as rufﬂed fur, labored breathing, crouching or huddling
behavior, sluggishness, and a loss of body weight. Previous research has demonstrated that body weight
loss is an excellent indicator of EHV-1 infection in the mouse (47). Three mice from each group were
sacriﬁced after 1 week for tissue collection and histopathological analysis.
Tissue collection and analysis. At 4 weeks after the 3rd vaccination and at 1 week postchallenge,
three mice from each group were anesthetized by inhalation of 2 to 3% isoﬂurane. The total blood
volume of each mouse was collected, and the mice were euthanized by cervical dislocation. The
blood was allowed to clot at room temperature for at least 30 min. Serum was centrifuged, collected, and
stored at ⫺20°C until use. The spleens were excised from the euthanized animals, minced, and passed
through a 10-mm-mesh-size nylon mesh cell strainer in RPMI 1640 medium with 10% heat-inactivated
fetal bovine serum (HI-FBS). Cell suspensions were pelleted by centrifugation at 400 ⫻ g for 7 min, and
the cell concentration was adjusted to 107 cells/ml for ﬂuorescence-activated cell sorting (FACS) analysis.
After challenge, the lung tissues from all four groups were collected and ﬁxed in 10% formalin for
immunohistochemistry.
Serum neutralization. The collected serum was used to neutralize 50 l of approximately 100 PFU
of EHV-1. After the serum samples were heated to 56°C for 1 h to inactivate complement, samples were
then diluted 1:10 in complete DMEM containing 10% heat-inactivated FBS. Fifty microliters of virus was
added to each dilution of serum to a total volume of 100 l. The addition of the virus made the ﬁnal
serum dilution 1:20. Serum-virus mixtures were placed on a rocker at room temperature for 1 h and
titrated on NBL-6 cell monolayers.
FITC ﬂow cytometry analysis with mouse serum. RK13 cells were infected with EHV-1 and were
disassociated by using 1 mM EDTA in phosphate-buffered saline (PBS). Fixation/permeabilization solution
was then added to the cells. Serum (1:20) from mice in the different groups was mixed with the cells after
two washes, and the mixture was incubated for 30 min at 37°C. Goat anti-mouse antibody conjugated
with ﬂuorescein isothiocyanate (FITC) was added to the suspension, and the mixture was incubated for
another 30 min at 37°C. The cells were washed twice by adding 3 ml buffer (1% HI-FBS in PBS). BD ﬁxative
solution was applied to the cells, and the cells were kept at 4°C until ﬂow cytometry analysis.
IFA analysis of mouse serum. Serum samples (1:20) from the mice in the different groups were
placed on equine herpesvirus 1 indirect ﬂuorescent-antibody (IFA) slides (catalog no. SLD-IFA-ERV;
Veterinary Medical Research & Development [VMRD]), and the slides were incubated for 30 min at 37°C.
An anti-equine IgG-FITC conjugate (catalog no. 043-10; VMRD) was added to the slides, and the slides
were incubated for another 30 min at 37°C after they were washed. The slides were observed under a
Nikon ﬂuorescence microscope.
Characterization of antibody subclass. To determine the antigen-speciﬁc antibody isotypes,
96-well plates were coated with 50 l of EHV-1-infected cell lysate (20 l/ml), and then serum from each
of the four groups of animals was diluted 1:100 and tested in duplicate. To detect the mouse IgG1, IgG2a,
IgG2b, IgG3, IgA, and IgM isotypes, anti-mouse IgG subclass-speciﬁc horseradish peroxidase-conjugated
secondary antibodies (1/10,000 dilution; Abcam) were used.
Analysis of immune responses using polychromatic ﬂow cytometry. The spleens were excised
from euthanized animals, minced, and passed through a 10-mm-mesh-size nylon mesh cell strainer
June 2017 Volume 91 Issue 12 e02445-16

jvi.asm.org 13

Downloaded from https://journals.asm.org/journal/jvi on 12 January 2022 by 2620:105:b001:1060:a90f:52aa:112b:ebee.

bVetera

Liu et al.

Journal of Virology

ACKNOWLEDGMENTS
We acknowledge the assistance provided by the staff of the Division of Biotechnology & Molecular Medicine and the Department of Biological Sciences, College of Basic
Sciences, Louisiana State University. We acknowledge critical reviews of the manuscript
by Paul Rider.
S.A.L. was supported by funds from the Louisiana Veterinary Diagnostic Laboratory.
The work was supported by the Division of Biotechnology & Molecular Medicine and
Cores of the Center for Experimental Infectious Disease Research (CEIDR), supported by
the NIH, NIGMS, grant P30GM110670.

REFERENCES
1. Trapp S, von Einem J, Hofmann H, Kostler J, Wild J, Wagner R, Beer M,
Osterrieder N. 2005. Potential of equine herpesvirus 1 as a vector for
immunization. J Virol 79:5445–5454. https://doi.org/10.1128/JVI.79.9
.5445-5454.2005.
2. Laval K, Favoreel HW, Poelaert KC, Van Cleemput J, Nauwynck HJ. 2015.
Equine herpesvirus type 1 enhances viral replication in CD172a⫹ monocytic cells upon adhesion to endothelial cells. J Virol 89:10912–10923.
https://doi.org/10.1128/JVI.01589-15.
3. Fuentealba N, Sguazza G, Scrochi M, Bravi M, Zanuzzi C, Corva S, Gimeno
E, Pecoraro M, Galosi C. 2014. Production of equine herpesvirus 1
recombinant glycoprotein D and development of an agar gel immunodiffusion test for serological diagnosis. J Virol Methods 202:15–18.
https://doi.org/10.1016/j.jviromet.2014.02.025.
4. Fuentealba NA, Zanuzzi CN, Scrochi MR, Sguazza GH, Bravi ME, Cid de la
Paz V, Corva SG, Portiansky EL, Gimeno EJ, Barbeito CG, Galosi CM. 2014.
Protective effects of intranasal immunization with recombinant glycoprotein D in pregnant BALB/c mice challenged with different strains of
equine herpesvirus 1. J Comp Pathol 151:384 –393. https://doi.org/10
.1016/j.jcpa.2014.06.003.
5. Packiarajah P, Walker C, Gilkerson J, Whalley JM, Love DN. 1998. Immune
responses and protective efﬁcacy of recombinant baculovirus-expressed
glycoproteins of equine herpesvirus 1 (EHV-1) gB, gC and gD alone or in
combinations in BALB/c mice. Vet Microbiol 61:261–278. https://doi.org/
10.1016/S0378-1135(98)00189-8.
June 2017 Volume 91 Issue 12 e02445-16

6. Zhang Y, Smith PM, Tarbet EB, Osterrieder N, Jennings SR, O’Callaghan
DJ. 1998. Protective immunity against equine herpesvirus type-1 (EHV-1)
infection in mice induced by recombinant EHV-1 gD. Virus Res 56:11–24.
https://doi.org/10.1016/S0168-1702(98)00054-9.
7. Azab W, Osterrieder N. 2012. Glycoproteins D of equine herpesvirus type
1 (EHV-1) and EHV-4 determine cellular tropism independently of integrins. J Virol 86:2031–2044. https://doi.org/10.1128/JVI.06555-11.
8. Weerasinghe CU, Learmonth GS, Gilkerson JR, Foote CE, Wellington JE,
Whalley JM. 2006. Equine herpesvirus 1 glycoprotein D expressed in E. coli
provides partial protection against equine herpesvirus infection in mice and
elicits virus-neutralizing antibodies in the horse. Vet Immunol Immunopathol 111:59 – 66. https://doi.org/10.1016/j.vetimm.2006.01.009.
9. Foote CE, Raidal SL, Pecenpetelovska G, Wellington JE, Whalley JM. 2006.
Inoculation of mares and very young foals with EHV-1 glycoproteins D
and B reduces virus shedding following respiratory challenge with
EHV-1. Vet Immunol Immunopathol 111:97–108. https://doi.org/10
.1016/j.vetimm.2006.01.012.
10. Foote CE, Love DN, Gilkerson JR, Rota J, Trevor-Jones P, Ruitenberg KM,
Wellington JE, Whalley JM. 2005. Serum antibody responses to equine
herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
Vet Immunol Immunopathol 105:47–57. https://doi.org/10.1016/j
.vetimm.2004.12.012.
11. Ruitenberg KM, Gilkerson JR, Wellington JE, Love DN, Whalley JM. 2001.
Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is
jvi.asm.org 14

Downloaded from https://journals.asm.org/journal/jvi on 12 January 2022 by 2620:105:b001:1060:a90f:52aa:112b:ebee.

(Fisher Scientiﬁc) in RPMI 1640 medium containing 10% HI-FBS and 1% Primocin. The cell suspensions
were then pelleted by centrifugation at 400 ⫻ g for 7 min at 4°C. Five milliliters of ammonium
chloride-potassium (ACK) lysing buffer was added to the cells. The cells were suspended and kept at room
temperature for 7 min, and then the volumes were adjusted to a total of 25 ml with RPMI 1640 medium. The
cell concentration was adjusted to 107 cells/ml after the cells were washed with RPMI 1640 medium. Three
different peptides (1 ng), 3 l Golgi-Plus, and 100 l of the splenocyte suspension (107 cells/ml) were gently
mixed. Then, the mixtures were incubated at 37°C and the splenocytes were stimulated for 6 h. The cells were
then stained with monoclonal rat anti-mouse CD3 antibody conjugated to peridinin chlorophyll protein-Cy5.5
(BD Biosciences), monoclonal rat anti-mouse CD4 antibody conjugated to phycoerythrin (BD Biosciences), rat
anti-mouse CD8a antibody conjugated to FITC (BD Biosciences), monoclonal rat anti-mouse IFN-␥ antibody
conjugated to allophycocyanin (BD Biosciences), and rat anti-mouse TNF antibody conjugated to BV510 (BD
Biosciences). FACS was performed using an Accuri C6 personal ﬂow cytometer. The data were analyzed using
FlowJo software (v10.1r1; FlowJo Enterprise).
Immunohistochemistry assay. Lung tissue samples were ﬁxed in 10% formalin, dehydrated through
increasing ethanol gradients, and parafﬁn embedded, before 4-m sections were obtained for hematoxylin and eosin (H&E) staining and immunohistochemical assays. The EHV-1 glycoprotein G1 was
detected using a rabbit anti-EHV-1 monoclonal murine antibody (courtesy of George Allen [now
deceased]), and the secondary antibody used was a goat anti-mouse IgG antibody (Abcam, USA). Finally,
the slides were visualized using a light microscope (Nikon, Japan) and pictured using an Olympus DP72
camera. The slides were analyzed and scored for cellular inﬂammation under a light microscope by a
pathologist who was blind to the treatment groups, as previously described (48). Brieﬂy, inﬂammatory
inﬁltrates were scored by enumerating the layers of inﬂammatory cells surrounding the vessels and
bronchioles. Zero to three layers of inﬂammatory cells were considered normal. Moderate to abundant
amounts of inﬁltrate (more than three layers of inﬂammatory cells surrounding 50% or more of the
circumference of the vessel or bronchioles) were considered abnormal. The number of abnormal
perivascular and peribronchial spaces divided by the total number of perivascular and peribronchial
spaces was the percentage reported as the pathology score. A total of up to 20 perivascular and
peribronchial spaces per lung were randomly selected and counted for each animal. Similarly, immunohistochemical staining was scored as the percentage of positively stained bronchiolar cells and
adjacent vascular endothelial cells. A total of approximately 70 to 100 bronchiolar epithelial cells and
peribronchiolar vascular endothelial cells were counted for each lung tissue section.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

hyperglycosylated and elicits a protective immune response in the
mouse model of EHV-1 disease. Virus Res 79:125–135. https://doi.org/
10.1016/S0168-1702(01)00337-9.
Csellner H, Walker C, Wellington JE, McLure LE, Love DN, Whalley JM.
2000. EHV-1 glycoprotein D (EHV-1 gD) is required for virus entry and
cell-cell fusion, and an EHV-1 gD deletion mutant induces a protective
immune response in mice. Arch Virol 145:2371–2385. https://doi.org/10
.1007/s007050070027.
Kydd JH, Townsend HG, Hannant D. 2006. The equine immune response
to equine herpesvirus-1: the virus and its vaccines. Vet Immunol Immunopathol 111:15–30. https://doi.org/10.1016/j.vetimm.2006.01.005.
Yeo WM, Osterrieder N, Stokol T. 2013. Equine herpesvirus type 1
infection induces procoagulant activity in equine monocytes. Vet Res
44:16. https://doi.org/10.1186/1297-9716-44-16.
Stanﬁeld BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied
AA, Walker JD, Kousoulas KG. 2014. A single intramuscular vaccination of
mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and
the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS One
9:e109890. https://doi.org/10.1371/journal.pone.0109890.
Walker C, Love DN, Whalley JM. 1999. Comparison of the pathogenesis
of acute equine herpesvirus 1 (EHV-1) infection in the horse and the
mouse model: a review. Vet Microbiol 68:3–13. https://doi.org/10.1016/
S0378-1135(99)00056-5.
Frampton AR, Jr, Smith PM, Zhang Y, Grafton WD, Matsumura T, Osterrieder N, O’Callaghan DJ. 2004. Meningoencephalitis in mice infected
with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E. Virus Genes 29:9 –17. https://doi.org/10
.1023/B:VIRU.0000032785.19420.14.
Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N. 2012. An
equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8
bluetongue virus (BTV-8) induces protection in a murine infection model.
PLoS One 7:e34425. https://doi.org/10.1371/journal.pone.0034425.
Bartels MJ, McNett DA, Timchalk C, Mendrala AL, Christenson WR,
Sangha GK, Brzak KA, Shabrang SN. 1998. Comparative metabolism of
ortho-phenylphenol in mouse, rat and man. Xenobiotica 28:579 –594.
https://doi.org/10.1080/004982598239335.
Bartels T, Steinbach F, Hahn G, Ludwig H, Borchers K. 1998. In situ study
on the pathogenesis and immune reaction of equine herpesvirus type 1
(EHV-1) infections in mice. Immunology 93:329 –334.
Wellington JE, Lawrence GL, Love DN, Whalley JM. 1996. Expression and
characterization of equine herpesvirus 1 glycoprotein D in mammalian
cell lines. Arch Virol 141:1785–1793. https://doi.org/10.1007/BF01718301.
Flowers CC, O’Callaghan DJ. 1992. Equine herpesvirus 1 glycoprotein D:
mapping of the transcript and a neutralization epitope. J Virol 66:
6451– 6460.
Ruitenberg KM, Love DN, Gilkerson JR, Wellington JE, Whalley JM. 2000.
Equine herpesvirus 1 (EHV-1) glycoprotein D DNA inoculation in horses
with pre-existing EHV-1/EHV-4 antibody. Vet Microbiol 76:117–127.
https://doi.org/10.1016/S0378-1135(00)00237-6.
Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM. 1999.
DNA-mediated immunization with glycoprotein D of equine herpesvirus
1 (EHV-1) in a murine model of EHV-1 respiratory infection. Vaccine
17:237–244. https://doi.org/10.1016/S0264-410X(98)00192-3.
Love DN, Bell CW, Whalley JM. 1992. Characterization of the glycoprotein
D gene products of equine herpesvirus 1 using a prokaryotic cell expression vector. Vet Microbiol 30:387–394. https://doi.org/10.1016/0378
-1135(92)90024-N.
Kydd JH, Wattrang E, Hannant D. 2003. Pre-infection frequencies of
equine herpesvirus-1 speciﬁc, cytotoxic T lymphocytes correlate with
protection against abortion following experimental infection of pregnant mares. Vet Immunol Immunopathol 96:207–217. https://doi.org/10
.1016/j.vetimm.2003.08.004.
Hannant D, Jessett DM, O’Neill T, Dolby CA, Cook RF, Mumford JA. 1993.
Responses of ponies to equid herpesvirus-1 ISCOM vaccination and
challenge with virus of the homologous strain. Res Vet Sci 54:299 –305.
https://doi.org/10.1016/0034-5288(93)90126-Z.
Bego MG, Bawiec D, Dandge D, Martino B, Dearing D, Wilson E, St Jeor
S. 2008. Development of an ELISA to detect Sin Nombre virus-speciﬁc
IgM from deer mice (Peromyscus maniculatus). J Virol Methods 151:
204 –210. https://doi.org/10.1016/j.jviromet.2008.05.008.
Song N, Lu F, Huang S, Ding G, Zhou Z, Liao Z. 2014. Effect of aqueous
extracts of Scutellaria baicalensis Georgi and Radix paeoniae Alba on the

June 2017 Volume 91 Issue 12 e02445-16

Journal of Virology

30.

31.

32.
33.

34.

35.
36.

37.

38.

39.

40.

41.
42.

43.

44.

45.

46.

47.

48.

serum IgG1 and IgG2a of the periodontitis mice. Zhonghua Kou Qiang
Yi Xue Za Zhi 49:89 –94. (In Chinese.)
Ebrahimpoor S, Pakzad SR, Ajdary S. 2013. IgG1 and IgG2a proﬁle of
serum antibodies to Leishmania major amastigote in BALB/c and
C57BL/6 mice. Iran J Allergy Asthma Immunol 12:361–367.
Koyama K, Ito Y. 2001. Comparative studies on the levels of serum IgG1
and IgG2a in susceptible B10.BR mice infected with different strains of
the intestinal nematode parasite Trichuris muris. Parasitol Res 87:
570 –572. https://doi.org/10.1007/s004360000351.
Berger A. 2000. Th1 and Th2 responses: what are they? BMJ 321:424.
https://doi.org/10.1136/bmj.321.7258.424.
Yadav D, Khuller G. 2001. Evaluation of the T cells and costimulatory
molecules in the protective efﬁcacy of 30 kDa secretory protein against
experimental tuberculosis. Immunol Cell Biol 79:207–212. https://doi
.org/10.1046/j.1440-1711.2001.00998.x.
Soboll G, Whalley JM, Koen MT, Allen GP, Fraser DG, Macklin MD, Swain
WF, Lunn DP. 2003. Identiﬁcation of equine herpesvirus-1 antigens
recognized by cytotoxic T lymphocytes. J Gen Virol 84:2625–2634.
https://doi.org/10.1099/vir.0.19268-0.
Allen GP, Kydd JH, Slater JD, Smith KC. 2004. Equid herpesvirus 1 and
equid herpesvirus 4 infections. Infect Dis Livestock 76:829 – 859.
Allen GP, Bolin DC, Bryant U, Carter CN, Giles RC, Harrison LR, Hong CB,
Jackson CB, Poonacha K, Wharton R, Williams NM. 2008. Prevalence of
latent, neuropathogenic equine herpesvirus-1 in the Thoroughbred
broodmare population of central Kentucky. Equine Vet J 40:105–110.
https://doi.org/10.2746/042516408X253127.
Allen G, Yeargan M, Costa LR, Cross R. 1995. Major histocompatibility
complex class I-restricted cytotoxic T-lymphocyte responses in horses
infected with equine herpesvirus 1. J Virol 69:606 – 612.
O’Flaherty BM, Matar CG, Wakeman BS, Garcia A, Wilke CA, Courtney CL,
Moore BB, Speck SH. 2015. CD8⫹ T cell response to gammaherpesvirus
infection mediates inﬂammation and ﬁbrosis in interferon gamma
receptor-deﬁcient mice. PLoS One 10:e0135719. https://doi.org/10.1371/
journal.pone.0135719.
McCarthy MK, Procario MC, Twisselmann N, Wilkinson JE, Archambeau
AJ, Michele DE, Day SM, Weinberg JB. 2015. Proinﬂammatory effects of
interferon gamma in mouse adenovirus 1 myocarditis. J Virol 89:
468 – 479. https://doi.org/10.1128/JVI.02077-14.
Mikloska Z, Cunningham AL. 2001. Alpha and gamma interferons inhibit
herpes simplex virus type 1 infection and spread in epidermal cells after
axonal transmission. J Virol 75:11821–11826. https://doi.org/10.1128/JVI
.75.23.11821-11826.2001.
Cantin E, Tanamachi B, Openshaw H. 1999. Role for gamma interferon in
control of herpes simplex virus type 1 reactivation. J Virol 73:3418 –3423.
Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital
herpes by establishing local memory T cells. Nature 491:463– 467.
https://doi.org/10.1038/nature11522.
Breathnach CC, Soboll G, Suresh M, Lunn DP. 2005. Equine herpesvirus-1
infection induces IFN-gamma production by equine T lymphocyte subsets. Vet Immunol Immunopathol 103:207–215. https://doi.org/10.1016/
j.vetimm.2004.09.024.
Smith PM, Zhang Y, Grafton WD, Jennings SR, O’Callaghan DJ. 2000.
Severe murine lung immunopathology elicited by the pathogenic
equine herpesvirus 1 strain RacL11 correlates with early production
of macrophage inﬂammatory proteins 1alpha, 1beta, and 2 and tumor
necrosis factor alpha. J Virol 74:10034 –10040. https://doi.org/10.1128/
JVI.74.21.10034-10040.2000.
Stanﬁeld BA, Pahar B, Chouljenko VN, Veazey R, Kousoulas KG. 2017.
Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine
VC2 stimulates the proliferation of mucosal T cells and germinal center
responses resulting in sustained production of highly neutralizing antibodies. Vaccine 35:536 –543. https://doi.org/10.1016/j.vaccine.2016.12
.018.
Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step Redmediated recombination for versatile high-efﬁciency markerless DNA
manipulation in Escherichia coli. Biotechniques 40:191–197. https://doi
.org/10.2144/000112096.
van Woensel PA, Goovaerts D, Markx D, Visser N. 1995. A mouse model
for testing the pathogenicity of equine herpes virus-1 strains. J Virol
Methods 54:39 – 49. https://doi.org/10.1016/0166-0934(95)00024-O.
Haeberle HA, Kuziel WA, Dieterich HJ, Casola A, Gatalica Z, Garofalo RP.
2001. Inducible expression of inﬂammatory chemokines in respiratory
syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J
Virol 75:878 – 890. https://doi.org/10.1128/JVI.75.2.878-890.2001.
jvi.asm.org 15

Downloaded from https://journals.asm.org/journal/jvi on 12 January 2022 by 2620:105:b001:1060:a90f:52aa:112b:ebee.

HSV-1-Based Vaccine for Equine Herpesvirus Infections

